MedTrace Logo

Retina is a Marker for Cerebrovascular Heath

NCT04753970 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-07-23

No results posted yet for this study

Summary

Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.

Conditions

  • Cerebral Small Vessel Diseases
  • Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
  • Cerebral Microbleeding
  • Sporadic White Matter Disease

Interventions

DRUG

Cilostazol

Cilostazol 100mg BID

Sponsors & Collaborators

Principal Investigators

  • Michelle P Lin, MD, MPH · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-09
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04753970 on ClinicalTrials.gov